1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 30
1.2.2 MARKETS COVERED 31
1.2.3 YEARS CONSIDERED FOR THE STUDY 31
1.3 CURRENCY 32
1.4 LIMITATIONS 32
1.5 STAKEHOLDERS 32
1.6 SUMMARY OF CHANGES 33

2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
2.2 RESEARCH APPROACH 34
FIGURE 1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY 34
2.2.1 SECONDARY DATA 35
2.2.1.1 Key data from secondary sources 35
2.2.2 PRIMARY DATA 36
2.2.2.1 Key data from primary sources 36
2.2.2.2 Key industry insights 37
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 38
2.3 MARKET SIZE ESTIMATION 38
2.3.1 BOTTOM-UP APPROACH 38
FIGURE 3 INFECTIOUS DISEASE DIAGNOSTICS MARKET: BOTTOM-UP APPROACH 39
FIGURE 4 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 39
2.3.2 TOP-DOWN APPROACH 40
FIGURE 5 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH 40
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 41
FIGURE 6 DATA TRIANGULATION METHODOLOGY 41
2.5 ASSUMPTIONS FOR THE STUDY 42
2.6 RISK ASSESSMENT 42
TABLE 1 RISK ASSESSMENT: INFECTIOUS DISEASE DIAGNOSTICS MARKET 42
2.7 COVID-19 HEALTH ASSESSMENT 43
2.8 COVID-19 ECONOMIC ASSESSMENT 43
2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 43
FIGURE 7 CRITERIA IMPACTING THE GLOBAL ECONOMY 44
FIGURE 8 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 45
2.10 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET 46

3 EXECUTIVE SUMMARY 47
FIGURE 9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION) 47
FIGURE 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION) 48
FIGURE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021 VS. 2026 (USD MILLION) 48
FIGURE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 49
FIGURE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION) 49

4 PREMIUM INSIGHTS 51
4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW 51
FIGURE 14 THE RISING ADOPTION OF POC DIAGNOSTICS IS EXPECTED TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD 51
4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION) 52
FIGURE 15 REAGENTS, KITS, AND CONSUMABLES SEGMENT TO COMMAND THE LARGEST SHARE OF THE MARKET, BY PRODUCT & SERVICE, IN 2021 52
4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION) 52
FIGURE 16 IMMUNODIAGNOSTICS TO HOLD THE LARGEST SHARE OF THE MARKET DURING THE FORECAST PERIOD 52
4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 53
FIGURE 17 DIAGNOSTIC LABORATORIES DOMINATE THE END-USER MARKET 53

5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
FIGURE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
5.2.1 DRIVERS 55
5.2.1.1 Global prevalence of infectious diseases and onset of COVID-19 55
5.2.1.2 Rising focus on R&D and funding in infectious disease diagnostics 55
5.2.1.3 Growing awareness for early disease diagnosis in developing countries 56
5.2.1.4 Rising technological advancements in infectious disease diagnostics 57
5.2.1.5 Shift in focus from centralized laboratories to decentralized POC testing 57
5.2.2 RESTRAINTS 58
5.2.2.1 Unfavorable reimbursement scenario 58
5.2.3 OPPORTUNITIES 58
5.2.3.1 Growth opportunities in growing economies 58
5.2.4 CHALLENGES 59
5.2.4.1 Changing regulatory landscape 59
5.2.4.2 Operational barriers 59
5.2.5 COVID-19 IMPACT ANALYSIS 59
5.3 PRICING ANALYSIS 60
TABLE 2 PRICING ANALYSIS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (2021) 60
5.4 PATENT ANALYSIS 62
5.4.1 POLYMERASE CHAIN REACTION 62
5.4.2 IMMUNODIAGNOSTICS 63
5.5 VALUE CHAIN ANALYSIS 64
FIGURE 19 VALUE CHAIN ANALYSIS OF THE INFECTIOUS DISEASE DIAGNOSTICS MARKET 64
5.6 SUPPLY CHAIN ANALYSIS 64
FIGURE 20 SUPPLY CHAIN ANALYSIS 65
5.7 ECOSYSTEM ANALYSIS 65
5.8 PORTER'S FIVE FORCES ANALYSIS 66
TABLE 3 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS 66
5.8.1 THREAT FROM NEW ENTRANTS 66
5.8.2 THREAT FROM SUBSTITUTES 66
5.8.3 BARGAINING POWER OF BUYERS 66
5.8.4 BARGAINING POWER OF SUPPLIERS 66
5.8.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS 67
5.9 PESTLE ANALYSIS 67
5.10 REGULATORY LANDSCAPE 68
5.10.1 NORTH AMERICA 68
5.10.1.1 US 68
5.10.1.2 Canada 68
5.10.2 EUROPE 68
5.10.3 ASIA PACIFIC 68
5.10.3.1 China 68
5.10.3.2 Japan 69
5.10.3.3 India 69
5.10.4 LATIN AMERICA 69
5.10.4.1 Brazil 69
5.10.4.2 Mexico 70
5.10.5 MIDDLE EAST 70
5.10.6 AFRICA 70
5.11 TRADE ANALYSIS 70
5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 70
TABLE 4 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016?2020 (USD MILLION) 70
TABLE 5 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016?2020 (TONS) 71
5.11.2 TRADE ANALYSIS FOR CULTURE MEDIA 71
TABLE 6 IMPORT DATA FOR CULTURE MEDIA, BY COUNTRY, 2016?2020 (USD MILLION) 71
TABLE 7 IMPORT DATA FOR CULTURE MEDIA, BY COUNTRY, 2016?2020 (TONS) 71
5.12 TECHNOLOGY ANALYSIS 72
5.13 YC-YCC SHIFT 72
FIGURE 21 YC-YCC SHIFT FOR THE INFECTIOUS DISEASE DIAGNOSTICS MARKET 72

6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 73
6.1 INTRODUCTION 74
TABLE 8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 74
6.2 REAGENTS, KITS, AND CONSUMABLES 74
6.2.1 REPEAT PURCHASE OF REAGENTS, KITS, AND CONSUMABLES DRIVES THE MARKET GROWTH 74
TABLE 9 INFECTIOUS DISEASE DIAGNOSTICS REAGENTS, KITS, AND CONSUMABLES MARKET, BY REGION, 2019-2026 (USD MILLION) 75
6.3 INSTRUMENTS 76
6.3.1 INCREASING NEED FOR FASTER & ACCURATE TEST RESULTS TO PROPEL THE MARKET GROWTH 76
TABLE 10 KEY PRODUCTS IN THE INSTRUMENTS MARKET 77
TABLE 11 INFECTIOUS DISEASE DIAGNOSTICS INSTRUMENTS MARKET, BY REGION, 2019-2026 (USD MILLION) 77
6.4 SOFTWARE & SERVICES 78
6.4.1 NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTIC TESTS 78
TABLE 12 INFECTIOUS DISEASE DIAGNOSTICS SOFTWARE & SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION) 78

7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING 79
7.1 INTRODUCTION 80
TABLE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2019-2026 (USD MILLION) 80
7.2 LABORATORY TESTING 80
7.2.1 OUTBREAK OF COVID-19 DRIVES DEMAND FOR LAB TESTS 80
TABLE 14 LABORATORY TESTING MARKET, BY REGION, 2019-2026 (USD MILLION) 81
7.3 POC TESTING 81
7.3.1 THE INCREASING ADOPTION OF POC TECHNOLOGIES DRIVES THE GROWTH OF THIS SEGMENT 81
TABLE 15 POC TESTING MARKET, BY REGION, 2019-2026 (USD MILLION) 82

8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY 83
8.1 INTRODUCTION 84
TABLE 16 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 84
8.2 IMMUNODIAGNOSTICS 85
8.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR COVID-19 DIAGNOSTICS DRIVE MARKET GROWTH 85
TABLE 17 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2019-2026 (USD MILLION) 85
8.3 POLYMERASE CHAIN REACTION 86
8.3.1 THE GROWING USE OF RT-PCR IN COVID-19 TESTS IS A MAJOR GROWTH DRIVER FOR THIS SEGMENT 86
TABLE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR PCR, BY REGION, 2019-2026 (USD MILLION) 86
8.4 CLINICAL MICROBIOLOGY 87
8.4.1 GROWING ADOPTION BY RESEARCHERS AND ACADEMIA IS EXPECTED TO DRIVE MARKET GROWTH 87
TABLE 19 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2019-2026 (USD MILLION) 87
8.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 88
8.5.1 COST-BENEFITS OF INAAT DRIVE DEMAND FOR THE TECHNOLOGY 88
TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2019-2026 (USD MILLION) 88
8.6 DNA SEQUENCING & NGS 89
8.6.1 INCREASING FOCUS ON PERSONALIZED MEDICINE IS A GROWTH DRIVER FOR THIS SEGMENT 89
TABLE 21 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY REGION, 2019-2026 (USD MILLION) 89
8.7 DNA MICROARRAYS 90
8.7.1 GROWING AWARENESS ABOUT ADVANCED TECHNOLOGIES TO DRIVE MARKET GROWTH 90
TABLE 22 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2019-2026 (USD MILLION) 90
8.8 OTHER TECHNOLOGIES 91
TABLE 23 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2019-2026 (USD MILLION) 91

9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE 92
9.1 INTRODUCTION 93
TABLE 24 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 93
9.2 COVID-19 93
9.2.1 HIGH AND GROWING CASE PREVALENCE ENSURES DEMAND FOR COVID-19 DIAGNOSTICS 93
TABLE 25 DISTRIBUTION OF CASES BY COUNTRY 94
TABLE 26 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION) 94
TABLE 27 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS) 94
TABLE 28 COVID-19 DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION) 95
9.3 HUMAN IMMUNODEFICIENCY VIRUS 95
9.3.1 THE HIGH PREVALENCE OF HIV WILL DRIVE THE MARKET GROWTH FOR THIS SEGMENT 95
TABLE 29 HIV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION) 95
TABLE 30 HIV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS) 96
9.4 HOSPITAL-ACQUIRED INFECTIONS 96
9.4.1 THE RISING BURDEN OF MRSA INFECTIONS IS A KEY FACTOR DRIVING THE MARKET GROWTH FOR THIS SEGMENT 96
TABLE 31 HAI DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION) 96
TABLE 32 HAI DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS) 97
9.5 HEPATITIS 97
9.5.1 THE GLOBAL PREVALENCE OF HEPATITIS IS A KEY FACTOR DRIVING MARKET GROWTH 97
TABLE 33 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION) 98
TABLE 34 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS) 98
TABLE 35 HEPATITIS DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION) 98
9.6 CHLAMYDIA TRACHOMATIS GENITAL INFECTIONS AND GONORRHEA 99
9.6.1 CT/NG INFECTIONS ARE THE MOST COMMON STDS 99
TABLE 36 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION) 99
TABLE 37 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS) 99
9.7 HUMAN PAPILLOMA VIRUS 100
9.7.1 TECHNOLOGICAL ADVANCEMENTS SUCH AS RAPID HPV DIAGNOSTICS TO DRIVE THE MARKET GROWTH FOR THIS SEGMENT 100
TABLE 38 HPV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION) 100
TABLE 39 HPV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS) 100
9.8 TUBERCULOSIS 101
9.8.1 THE INCREASING BURDEN OF TB GLOBALLY TO DRIVE THE MARKET GROWTH OF THIS SEGMENT 101
TABLE 40 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION) 101
TABLE 41 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS) 101
TABLE 42 TUBERCULOSIS DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION) 102
9.9 INFLUENZA 102
9.9.1 RISING FOCUS ON CONTAINING THE SPREAD OF INFLUENZA 102
TABLE 43 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION) 102
TABLE 44 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS) 103
TABLE 45 INFLUENZA DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION) 103
9.10 OTHER INFECTIOUS DISEASES 103
TABLE 46 OTHER INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION) 103

10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER 104
10.1 INTRODUCTION 105
TABLE 47 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 105
10.2 DIAGNOSTIC LABORATORIES 106
10.2.1 INCREASING OUTSOURCING TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS DRIVES MARKET GROWTH 106
TABLE 48 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2019-2026 (USD MILLION) 106
10.3 HOSPITALS & CLINICS 107
10.3.1 HOSPITALS & CLINICS SHOW INCREASING ADOPTION RATE OF INFECTIOUS DISEASE DIAGNOSTIC TOOLS 107
TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2019-2026 (USD MILLION) 107
10.4 ACADEMIC RESEARCH INSTITUTES 108
10.4.1 FOCUS ON DEVELOPING INNOVATIVE TESTS DRIVES MARKET GROWTH 108
TABLE 50 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2019-2026 (USD MILLION) 108
10.5 OTHER END USERS 109
TABLE 51 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2019-2026 (USD MILLION) 109

11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION 110
11.1 INTRODUCTION 111
TABLE 52 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION) 111
11.2 NORTH AMERICA 111
FIGURE 22 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT 112
TABLE 53 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION) 112
TABLE 54 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 113
TABLE 55 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 113
TABLE 56 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 113
TABLE 57 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 114
11.2.1 US 114
11.2.1.1 US dominates the market in North America and globally 114
TABLE 58 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 115
TABLE 59 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 115
TABLE 60 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 115
TABLE 61 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 116
11.2.2 CANADA 116
11.2.2.1 Focus on affordable tests drives the market growth 116
TABLE 62 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 116
TABLE 63 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 117
TABLE 64 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 117
TABLE 65 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 118
11.3 EUROPE 118
TABLE 66 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION) 118
TABLE 67 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 119
TABLE 68 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 119
TABLE 69 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 119
TABLE 70 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 120
11.3.1 GERMANY 120
11.3.1.1 Germany holds the largest share of the market in Europe 120
TABLE 71 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 121
TABLE 72 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 121
TABLE 73 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 121
TABLE 74 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 122
11.3.2 ITALY 122
11.3.2.1 Adoption of advanced diagnostic technologies to drive market growth in Italy 122
TABLE 75 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 122
TABLE 76 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 123
TABLE 77 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 123
TABLE 78 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 124
11.3.3 FRANCE 124
11.3.3.1 Rising R&D expenditure in France 124
TABLE 79 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 124
TABLE 80 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 125
TABLE 81 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 125
TABLE 82 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 125
11.3.4 SPAIN 126
11.3.4.1 Healthcare infrastructural improvements indicate favorable prospects for market growth 126
TABLE 83 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 126
TABLE 84 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 126
TABLE 85 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 127
TABLE 86 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 127
11.3.5 UK 128
11.3.5.1 The increasing number of accredited diagnostic laboratories propels market growth in the UK 128
TABLE 87 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 128
TABLE 88 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 128
TABLE 89 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 129
TABLE 90 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 129
11.3.6 REST OF EUROPE 129
TABLE 91 ROE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 130
TABLE 92 ROE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 130
TABLE 93 ROE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 131
TABLE 94 ROE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 131
11.4 ASIA PACIFIC 132
FIGURE 23 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT 133
TABLE 95 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION) 133
TABLE 96 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 134
TABLE 97 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 134
TABLE 98 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 134
TABLE 99 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 135
11.4.1 CHINA 135
11.4.1.1 Growing access to modern healthcare and outbreak of COVID-19 135
TABLE 100 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 135
TABLE 101 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 136
TABLE 102 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 136
TABLE 103 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 137
11.4.2 JAPAN 137
11.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan 137
TABLE 104 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 137
TABLE 105 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 138
TABLE 106 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 138
TABLE 107 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 139
11.4.3 INDIA 139
11.4.3.1 Increasing private & public investments in the country's healthcare system will drive market growth 139
TABLE 108 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 139
TABLE 109 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 140
TABLE 110 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 140
TABLE 111 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 141
11.4.4 REST OF ASIA PACIFIC 141
TABLE 112 ROAPAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 141
TABLE 113 ROAPAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 142
TABLE 114 ROAPAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 142
TABLE 115 ROAPAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 143
11.5 LATIN AMERICA 143
11.5.1 RISING DISEASE PREVALENCE AND HEALTHCARE EXPENDITURE HAVE DRAWN FOREIGN PLAYERS TO LATAM MARKETS 143
TABLE 116 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 143
TABLE 117 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 144
TABLE 118 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 144
TABLE 119 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 145
11.6 MIDDLE EAST & AFRICA 145
11.6.1 RISING ACCESS TO ADVANCED TECHNOLOGIES AND GROWING INVESTMENTS WILL SUPPORT MARKET GROWTH 145
TABLE 120 MEA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION) 145
TABLE 121 MEA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION) 146
TABLE 122 MEA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION) 146
TABLE 123 MEA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION) 147

12 COMPETITIVE LANDSCAPE 148
12.1 OVERVIEW 148
FIGURE 24 KEY STRATEGIES IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET (2018-2021) 148
12.2 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 149
FIGURE 25 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET 149
12.3 MARKET SHARE ANALYSIS 150
FIGURE 26 INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2020) 150
12.3.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET RANKING, BY DISEASE TYPE 150
12.3.1.1 Hepatitis 150
TABLE 124 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY KEY PLAYER, 2020 150
12.3.1.2 HIV 151
TABLE 125 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY KEY PLAYER, 2020 151
12.3.1.3 HPV 151
TABLE 126 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY KEY PLAYER, 2020 151
12.3.1.4 Influenza 151
TABLE 127 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY KEY PLAYER, 2020 151
12.3.1.5 COVID-19 152
TABLE 128 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY KEY PLAYER, 2020 152
12.4 COMPANY EVALUATION QUADRANT 152
12.4.1 STARS 152
12.4.2 EMERGING LEADERS 152
12.4.3 PERVASIVE PLAYERS 153
12.4.4 PARTICIPANTS 153
FIGURE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT, 2020 153
12.5 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2020) 154
12.5.1 PROGRESSIVE COMPANIES 154
12.5.2 STARTING BLOCKS 154
12.5.3 RESPONSIVE COMPANIES 154
12.5.4 DYNAMIC COMPANIES 154
FIGURE 28 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2020) 155
12.6 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS 156
FIGURE 29 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET 156
12.7 COMPETITIVE SCENARIO 156
12.7.1 MARKET EVALUATION MATRIX, 2018-2020 156
12.7.2 INFECTIOUS DISEASE DIAGNOSTICS: PRODUCT LAUNCHES & APPROVALS 157
TABLE 129 KEY PRODUCT LAUNCHES & APPROVALS 157
12.7.3 INFECTIOUS DISEASE DIAGNOSTICS: DEALS 158
TABLE 130 KEY DEALS 158
12.7.4 INFECTIOUS DISEASE DIAGNOSTICS: OTHER DEVELOPMENTS 158
TABLE 131 OTHER KEY DEVELOPMENTS 158

13 COMPANY PROFILES 159
13.1 KEY PLAYERS 159
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, right to win)* 13.1.1 ABBOTT LABORATORIES 159
TABLE 132 ABBOTT LABORATORIES: BUSINESS OVERVIEW 159
FIGURE 30 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020) 160
13.1.2 F. HOFFMANN-LA ROCHE 164
TABLE 133 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW 164
FIGURE 31 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2020) 165
13.1.3 BIOMÉRIEUX SA 170
TABLE 134 BIOMÉRIEUX SA: BUSINESS OVERVIEW 170
FIGURE 32 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020) 170
13.1.4 THERMO FISHER SCIENTIFIC 176
TABLE 135 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 176
FIGURE 33 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020) 176
13.1.5 DANAHER CORPORATION 181
TABLE 136 DANAHER CORPORATION: BUSINESS OVERVIEW 181
FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 181
13.1.6 QUIDEL CORPORATION 186
TABLE 137 QUIDEL CORPORATION: BUSINESS OVERVIEW 186
FIGURE 35 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020) 186
13.1.7 HOLOGIC 191
TABLE 138 HOLOGIC: BUSINESS OVERVIEW 191
FIGURE 36 HOLOGIC: COMPANY SNAPSHOT (2020) 191
13.1.8 PERKINELMER 194
TABLE 139 PERKINELMER: BUSINESS OVERVIEW 194
FIGURE 37 PERKINELMER: COMPANY SNAPSHOT (2020) 194
13.1.9 BECTON, DICKINSON AND COMPANY 198
TABLE 140 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 198
FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020) 198
13.1.10 SIEMENS HEALTHINEERS AG 202
TABLE 141 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 202
FIGURE 39 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020) 202
13.1.11 DIASORIN S.P.A 206
TABLE 142 DIASORIN S.P.A: BUSINESS OVERVIEW 206
FIGURE 40 DIASORIN S.P.A: COMPANY SNAPSHOT (2020) 206
13.1.12 BIO-RAD LABORATORIES 212
TABLE 143 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 212
FIGURE 41 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020) 212
13.1.13 QIAGEN 216
TABLE 144 QIAGEN: BUSINESS OVERVIEW 216
FIGURE 42 QIAGEN N.V.: COMPANY SNAPSHOT (2020) 217
13.1.14 GRIFOLS S.A. 220
TABLE 145 GRIFOLS S.A.: BUSINESS OVERVIEW 220
FIGURE 43 GRIFOLS S.A.: COMPANY SNAPSHOT (2020) 220
13.1.15 ORTHO CLINICAL DIAGNOSTICS 222
TABLE 146 ORTHO CLINICAL DIAGNOSTICS: BUSINESS OVERVIEW 222
FIGURE 44 ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT (2020) 222
13.1.16 SYSMEX CORPORATION 225
TABLE 147 SYSMEX CORPORATION: BUSINESS OVERVIEW 225
FIGURE 45 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020) 225
13.2 OTHER PLAYERS 227
13.2.1 LUMINEX CORPORATION 227
13.2.2 MERIDIAN BIOSCIENCE 229
13.2.3 TRINITY BIOTECH 233
13.2.4 CHEMBIO DIAGNOSTIC SYSTEMS 234
13.2.5 ORASURE TECHNOLOGIES 237
13.2.6 SEEGENE 238
13.2.7 CO-DIAGNOSTICS 241
13.2.8 GENETIC SIGNATURES 243
13.2.9 EPITOPE DIAGNOSTICS 245
13.2.10 TRIVITRON HEALTHCARE 247
13.2.11 ELITECHGROUP 249
13.2.12 MERIL LIFESCIENCES PVT. LTD. 252
13.2.13 INBIOS INTERNATIONAL 253
13.2.14 ABACUS DIAGNOSTICA OY 255
*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, right to win might not be captured in case of unlisted companies. 14 APPENDIX 256
14.1 INSIGHTS FROM INDUSTRY EXPERTS 256
14.2 DISCUSSION GUIDE 257
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 260
14.4 AVAILABLE CUSTOMIZATIONS 262
14.5 RELATED REPORTS 262
14.6 AUTHOR DETAILS 263